type and frequency of pregnancy complications
Time frame · at end of study
We will quantify a set of pregnancy and offspring outcomes and complications.
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
Status
Recruiting
Phase
Not applicable
Enrollment
90
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Background: Lipodystrophy is a health problem in which the body does not have enough fat tissue. People with lipodystrophy may not make enough of the hormone leptin. Leptin regulates hunger. Low leptin levels trigger hunger. People with lipodystrophy can have many health problems. They may take a drug (metreleptin) that mimics leptin. Little is known about how taking metreleptin may affect a pregnancy. Metreleptin may be helpful or harmful to pregnant women. It may also affect the health of the child who is born. Objective: This natural history study will collect data about the effects of taking metreleptin while pregnant. Eligibility: Women aged 18 years or older with lipodystrophy who have been pregnant. Women who did and who did not take metreleptin during their pregnancies are needed. Children of women with lipodystrophy who took this drug during pregnancy are also needed. Design: Participants will have 1 study visit. This visit may be by phone, by telehealth, or in-person. Participants will answer questions about their pregnancies. They will discuss any health problems they had. They will be asked about any medicines they took before and during their pregnancies. They will be asked about the health of their children. Participants medical records will be reviewed. Participants may need to provide a blood sample. They may also be asked to provide a sample of breastmilk. Participants children may also be asked to provide a blood sample....
Full detailed description
Study Description: Single-site cross-sectional study of women with lipodystrophy who had pregnancies during which they were or were not exposed to metreleptin, and the offspring of women whose offspring were exposed to metreleptin during pregnancy. The study involves secondary use of data and samples from other studies in which these subjects participated, review of outside medical records, and collection of a single blood specimen if a biobanked specimen is not available. The hypotheses are: 1. Pregnancy complications will be less prevalent and severe in women with lipodystrophy who took metreleptin during pregnancy compared to those who did not, due the beneficial effects of metreleptin on metabolic complications of lipodystrophy. 2. Anti-leptin antibodies may be detected in some offspring born to women with lipodystrophy treated with metreleptin during pregnancy, but these antibodies will not be associated with adverse health outcomes. Objectives: Primary: Determine pregnancy outcomes, including type and frequency of pregnancy complications in women treated with metreleptin during pregnancy vs. untreated pregnancies. Secondary: Determine if anti-leptin antibodies are detectable in offspring of women treated with metreleptin during pregnancy. Endpoints: Primary Endpoint: We will quantify a set of pregnancy and offspring outcomes and complications. Secondary Endpoints: Frequency and type of anti-leptin antibodies.
Interventions
Treatment arms and agents.
No intervention details reported.
Timeline
From registration to results.
First posted
Jun 15, 2022
Study start
Sep 7, 2022
Primary completion
Mar 1, 2028
Study completion
Mar 1, 2029
Results posted
Not reported
Registry updated
Jun 15, 2026
Outcomes
What the study measures.
Primary outcomes
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 6 Months
- Maximum age
- 98 Years
- Sex
- ALL
- Healthy volunteers
- No
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Women with lipodystrophy who had pregnancies with or without use of metreleptin: * Female, aged \>= 18 years * Clinical diagnosis of non-HIV associated generalized or partial lipodystrophy * History of one or more pregnancies * Offspring of women with lipodystrophy who had pregnancies while taking metreleptin: * Males or females aged \>=1 month * Mothers took metreleptin during their pregnancy * Availability of a biobanked blood specimen or willingness to provide a blood specimen Note that subjects treated with metreleptin during pregnancy may participate in this study regardless of the participation of their offspring. EXCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must not meet any of the following criteria: * Inability of subject or guardian to understand or the unwillingness to sign a written informed consent document (except as noted below with \*) * Pregnancy. * Subjects who otherwise meet inclusion/exclusion criteria but who are not reachable to obtain informed consent may be included under a waiver of consent.
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Metreleptin.
NCT IDStudyPhase / statusEnrollmentUpdated
Metreleptin in Anorexia Nervosa
Gabriella Milos · Anorexia Nervosa
Phase 2
Recruiting
50
2026-07
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
Regeneron · Generalized Lipodystrophy
Phase 3
Completed
9
2026-07
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Diabetes · Lipodystrophy
Phase 2
Active, not recruiting
29
2026-07
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
Amryt Pharma · Generalized Lipodystrophy
Phase 3
Terminated
1
2026-07
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Lipodystrophy · Diabetes
Phase 3
Active, not recruiting
24
2026-07
MEASuRE: Metreleptin Effectiveness And Safety Registry
Chiesi Farmaceutici S.p.A. · Generalised Lipodystrophy · Partial Lipodystrophy
Not applicable
Recruiting
100
2026-07
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Chiesi Farmaceutici S.p.A. · Familial Partial Lipodystrophy
Phase 3
Recruiting
24
2026-07
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
Chiesi Farmaceutici S.p.A. · Partial Lipodystrophy
Phase 3
Active, not recruiting
69
2026-06
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.